Hourly refreshFri, Sep 25, 2026

Press Release Database

Recent press releases, indexed by topic.
AllFinanceCryptoAISaaSHealthcareReal EstateEnergyRetailAutomotiveGamingMediaEducation
Results
Showing all · 100166 itemsDownloadExcelTXT
Finance

Class Action Lawsuit Reminder from Pomerantz LLP for Investors of iTonic ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against iTonic Holdings Ltd (f/k/a Pheton Holdings Ltd) ("Pheton" or the "Company") (NASDAQ:ITOC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Pheton and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 28, 2026, ..

Sep 25 · 11:01PR-Inside
Finance

Pomerantz LLP Updates Shareholders on Legal Action Brought Against ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Capricor and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 28, 2026, to ask the Court ..

Sep 25 · 11:01PR-Inside
Finance · AI

Class Action Litigation Filed by Pomerantz LLP for Investors of Datavault ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT) and certain officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 2:26-cv-05548, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Datavault AI securities between September 4, 2024 and October 30, 2025, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' ..

Sep 25 · 11:01PR-Inside
Finance

Class Action Reminder from Pomerantz LLP for Investors of Wise Group ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Wise Group plc ("Wise" or the "Company") (NASDAQ:WSE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Wise and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 29, 2026, to ask the Court ..

Sep 25 · 11:01PR-Inside
Finance

Pomerantz LLP Notifies Investors of Class Action Lawsuit Against Pentair ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Pentair plc ("Pentair" or the "Company") (NYSE:PNR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Pentair and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until October 2, 2026, to ask the Court to ..

Sep 25 · 11:01PR-Inside
In the wire

Pharmaceutical Contract Development And Manufacturing Organization Market: Autoimmune Disease Pipelines Are Reshaping Demand

Market Overview & Size The global pharmaceutical CDMO industry has moved well past its early role as a low-cost manufacturing backup option — it is [read full press release...]

Sep 25 · 11:00Express Press Release
Education

APIA Scholars Announces Academic Year 2026-2027 Scholarship Cohort

APIA Scholars is proud to announce that for the 2026-2027 academic year, we are supporting over 1,000 students pursuing higher education across the United States and Pacific with scholarships and additional grant opportunities. Among these Scholars, the new AY2026-2027 cohort features 493...

Sep 25 · 11:00PRWeb
In the wire

ATA Critical Event Services Expands From Three Partners to a Network of More Than 20

Growing industry interest drives a broader network of incident response, investigation, engineering, security, and recovery capabilities

Sep 25 · 11:00Newswire.com
In the wire

Buffalo Potash Completes Final Horizontal Well and Concludes Successful Drilling Program

HighlightsCompleted third and final horizontal well, concluding the drilling program at the Disley Initial Production Module;All five wells are now complete, comprising two vertical wells and three horizontal wells, and the full subsurface foundation for Buffalo's HLD mining method is in place as designed; Each of the three horizontal wells made contact with approximately 95% of the target clay seam, with packer systems installed along all three wells as planned; and Completions and equipping...

Sep 25 · 11:00mlpr-newsfile
Finance

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of Action

Sep 25 · 11:00GlobeNewswire
Finance · Automotive

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis

Sep 25 · 11:00GlobeNewswire
Finance · Healthcare

Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion

Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM

Sep 25 · 11:00GlobeNewswire
← Prev123…8348Next →